Poteligeo for the Treatment of Mycosis Fungoides and Sezary Syndrome
Poteligeo® (mogamulizumab-kpkc) is a monoclonal antibody (mAb) indicated for the treatment of mycosis fungoides and Sézary syndrome in adults.
Trending:
Poteligeo® (mogamulizumab-kpkc) is a monoclonal antibody (mAb) indicated for the treatment of mycosis fungoides and Sézary syndrome in adults.
Cablivi (caplacizumab) is a bivalent anti-Von Willebrand factor (vWF) nanobody indicated for the treatment of...
Read More...
Carnexiv (carbamazepine) is an injectable formulation developed by Lundbeck for partial, generalised tonic-clonic seizures in...
Read More...